Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q3 2019 Earnings Presentation
8 slides from Angiodynamics's earnings presentation, Apr 2, 2019
Slide 1: AngioDynamics Third Quarter 2019 Earnings Presentation
AngioDynamics Third Quarter 2019 Earnings PresentationApril 2, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c
Slide 3: Third Quarter 2019 Highlights
Third Quarter 2019 Highlights Financial Performance Revenue of $86.3 million, compared to $83.9 million a year ago. Organic revenue was $83.2 million for the third quarter.Gross Margin of 54.1%, down 10 bps year over year. Expect full-year gross margin to be between 54% and 55%.Adjusted EPS of $0.19
Slide 4: Third Quarter and Year-to-Date FY 2019 Results (unaudited)
Third Quarter and Year-to-Date FY 2019 Results (unaudited) $ in thousands (except per share data) FY2019 Q3 Results FY2018Q3 Results Change FY2019 YTD Results FY2018 YTD Results Change Revenue- Vascular Interventions and Therapies- Vascular Access- Oncology - United States- International $86,34150,1
Slide 5: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation
Slide 6: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Amounts in thousands Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Adjustment to reflect the income tax provision on
Slide 7: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS Amounts in thousands
Slide 8: Growth Through Focus, Execution, Accountability
Growth 7HROUGH Focus) Execution! Accountability ® angiodynamics